Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

A synthetic-lethality RNAi screen reveals an ERK-mTOR co-targeting pro-apoptotic switch in PIK3CA+ oral cancers.

Yamaguchi K, Iglesias-Bartolomé R, Wang Z, Callejas-Valera JL, Amornphimoltham P, Molinolo AA, Cohen EE, Califano JA, Lippman SM, Luo J, Gutkind JS.

Oncotarget. 2016 Mar 8;7(10):10696-709. doi: 10.18632/oncotarget.7372.

2.

mTOR co-targeting in cetuximab resistance in head and neck cancers harboring PIK3CA and RAS mutations.

Wang Z, Martin D, Molinolo AA, Patel V, Iglesias-Bartolome R, Degese MS, Vitale-Cross L, Chen Q, Gutkind JS.

J Natl Cancer Inst. 2014 Aug 5;106(9). pii: dju215. doi: 10.1093/jnci/dju215. Print 2014 Sep.

3.

Prevention of tumor growth driven by PIK3CA and HPV oncogenes by targeting mTOR signaling with metformin in oral squamous carcinomas expressing OCT3.

Madera D, Vitale-Cross L, Martin D, Schneider A, Molinolo AA, Gangane N, Carey TE, McHugh JB, Komarck CM, Walline HM, William WN Jr, Seethala RR, Ferris RL, Gutkind JS.

Cancer Prev Res (Phila). 2015 Mar;8(3):197-207. doi: 10.1158/1940-6207.CAPR-14-0348. Epub 2015 Feb 13.

4.

Relationships between signaling pathway usage and sensitivity to a pathway inhibitor: examination of trametinib responses in cultured breast cancer lines.

Leung EY, Kim JE, Askarian-Amiri M, Rewcastle GW, Finlay GJ, Baguley BC.

PLoS One. 2014 Aug 29;9(8):e105792. doi: 10.1371/journal.pone.0105792. eCollection 2014.

5.

PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation.

Anderson GR, Wardell SE, Cakir M, Crawford L, Leeds JC, Nussbaum DP, Shankar PS, Soderquist RS, Stein EM, Tingley JP, Winter PS, Zieser-Misenheimer EK, Alley HM, Yllanes A, Haney V, Blackwell KL, McCall SJ, McDonnell DP, Wood KC.

Sci Transl Med. 2016 Dec 14;8(369):369ra175.

6.

Response of head and neck squamous cell carcinoma cells carrying PIK3CA mutations to selected targeted therapies.

Wirtz ED, Hoshino D, Maldonado AT, Tyson DR, Weaver AM.

JAMA Otolaryngol Head Neck Surg. 2015 Jun;141(6):543-9. doi: 10.1001/jamaoto.2015.0471.

7.

Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors.

Sheppard KE, Cullinane C, Hannan KM, Wall M, Chan J, Barber F, Foo J, Cameron D, Neilsen A, Ng P, Ellul J, Kleinschmidt M, Kinross KM, Bowtell DD, Christensen JG, Hicks RJ, Johnstone RW, McArthur GA, Hannan RD, Phillips WA, Pearson RB.

Eur J Cancer. 2013 Dec;49(18):3936-44. doi: 10.1016/j.ejca.2013.08.007. Epub 2013 Sep 3.

PMID:
24011934
8.

Epithelial to mesenchymal transition is associated with rapamycin resistance.

Holder AM, Akcakanat A, Adkins F, Evans K, Chen H, Wei C, Milton DR, Li Y, Do KA, Janku F, Meric-Bernstam F.

Oncotarget. 2015 Aug 14;6(23):19500-13.

9.

Evaluation of In Vitro Activity of the Class I PI3K Inhibitor Buparlisib (BKM120) in Pediatric Bone and Soft Tissue Sarcomas.

Anderson JL, Park A, Akiyama R, Tap WD, Denny CT, Federman N.

PLoS One. 2015 Sep 24;10(9):e0133610. doi: 10.1371/journal.pone.0133610. eCollection 2015.

10.

Ridaforolimus improves the anti-tumor activity of dual HER2 blockade in uterine serous carcinoma in vivo models with HER2 gene amplification and PIK3CA mutation.

Hernandez SF, Chisholm S, Borger D, Foster R, Rueda BR, Growdon WB.

Gynecol Oncol. 2016 Jun;141(3):570-579. doi: 10.1016/j.ygyno.2016.03.027. Epub 2016 Apr 1.

PMID:
27017985
11.

Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.

Zhou Q, Lui VW, Lau CP, Cheng SH, Ng MH, Cai Y, Chan SL, Yeo W.

Biochem Pharmacol. 2012 May 1;83(9):1146-58. doi: 10.1016/j.bcp.2012.01.013. Epub 2012 Jan 20.

PMID:
22285225
12.

Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.

Guenther MK, Graab U, Fulda S.

Cancer Lett. 2013 Sep 1;337(2):200-9. doi: 10.1016/j.canlet.2013.05.010. Epub 2013 May 16.

PMID:
23684925
13.

A retroinhibition approach reveals a tumor cell-autonomous response to rapamycin in head and neck cancer.

Amornphimoltham P, Patel V, Leelahavanichkul K, Abraham RT, Gutkind JS.

Cancer Res. 2008 Feb 15;68(4):1144-53. doi: 10.1158/0008-5472.CAN-07-1756.

14.

Patient-derived xenografts reveal limits to PI3K/mTOR- and MEK-mediated inhibition of bladder cancer.

Cirone P, Andresen CJ, Eswaraka JR, Lappin PB, Bagi CM.

Cancer Chemother Pharmacol. 2014 Mar;73(3):525-38. doi: 10.1007/s00280-014-2376-1. Epub 2014 Jan 19.

PMID:
24442130
15.

Kinome RNAi Screens Reveal Synergistic Targeting of MTOR and FGFR1 Pathways for Treatment of Lung Cancer and HNSCC.

Singleton KR, Hinz TK, Kleczko EK, Marek LA, Kwak J, Harp T, Kim J, Tan AC, Heasley LE.

Cancer Res. 2015 Oct 15;75(20):4398-406. doi: 10.1158/0008-5472.CAN-15-0509. Epub 2015 Sep 10.

16.

Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer.

Vujic I, Sanlorenzo M, Posch C, Esteve-Puig R, Yen AJ, Kwong A, Tsumura A, Murphy R, Rappersberger K, Ortiz-Urda S.

Oncotarget. 2015 Jan 20;6(2):969-78.

17.

Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells.

Grabinski N, Ewald F, Hofmann BT, Staufer K, Schumacher U, Nashan B, Jücker M.

Mol Cancer. 2012 Nov 20;11:85. doi: 10.1186/1476-4598-11-85.

18.

Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models.

Gozgit JM, Squillace RM, Wongchenko MJ, Miller D, Wardwell S, Mohemmad Q, Narasimhan NI, Wang F, Clackson T, Rivera VM.

Cancer Chemother Pharmacol. 2013 May;71(5):1315-23. doi: 10.1007/s00280-013-2131-z. Epub 2013 Mar 7.

PMID:
23468082
19.

Sorafenib enhances the therapeutic efficacy of rapamycin in colorectal cancers harboring oncogenic KRAS and PIK3CA.

Gulhati P, Zaytseva YY, Valentino JD, Stevens PD, Kim JT, Sasazuki T, Shirasawa S, Lee EY, Weiss HL, Dong J, Gao T, Evers BM.

Carcinogenesis. 2012 Sep;33(9):1782-90. doi: 10.1093/carcin/bgs203. Epub 2012 Jun 13.

20.

Combination of mTOR and EGFR targeting in an orthotopic xenograft model of head and neck cancer.

Bozec A, Ebran N, Radosevic-Robin N, Sudaka A, Monteverde M, Toussan N, Etienne-Grimaldi MC, Nigro CL, Merlano M, Penault-Llorca F, Milano G.

Laryngoscope. 2016 Apr;126(4):E156-63. doi: 10.1002/lary.25754. Epub 2015 Nov 24.

PMID:
26597440

Supplemental Content

Support Center